Irish-based medical technology company, Vertigenius, has successfully secured over €2.1m in funding for the development of cutting-edge technology designed to treat vertigo. This funding, led by Atlantic Bridge, with investments from Ascentifi and Enterprise Ireland, marks a significant milestone for the company, positioning them for substantial success in the near future.
Vertigenius has developed a wearable head sensor and software, aimed at allowing therapists to prescribe and monitor exercises performed by patients, as well as track their symptoms. This technology not only enables patients to carry out rehabilitation exercises at home, but also provides valuable insights into the effectiveness of treatments.
The Chief Executive Officer of Vertigenius, Mark Barry, expressed his enthusiasm for the potential impact of their technology, stating, “Worldwide, patients diagnosed with vertigo often face long waiting lists or even a lack of access to treatment altogether. Our mission is to provide early access to top-quality care for vertigo patients, ultimately improving the lives of millions of people.”
Dr. Dara Meldrum, the mastermind behind the technology, developed the foundation of the company’s innovative approach at Trinity College Dublin. With a dedicated and experienced team led by Mark Barry, coupled with the strong market potential, Vertigenius’ vision for pioneering advancements in vertigo treatment is well on its way to becoming a reality.
In addition to facilitating the development of the treatment technology, the funding will also lead to the creation of ten new job opportunities within the company. Furthermore, it will support the continued product development and expansion into the UK and US markets. The company is currently making strides in Ireland, with its software being employed by clinics and over 1,000 patients. Plans are already in motion to venture into the UK market by mid-2024, followed by an expansion into the US market by early next year.
Conor O’Sullivan, the Investment Director at Atlantic Bridge, expressed their excitement at the prospect of collaborating with Vertigenius. “We look forward to partnering with Vertigenius as they pioneer advancements in vertigo treatment. The company’s innovative approach, combined with their experienced team and strong market potential, positions the company for significant success.”
The future looks promising for Vertigenius, as they continue their mission to revolutionize the treatment of vertigo and make a positive impact on the lives of vertigo patients worldwide. With the innovative technology at their disposal and the support of key investors, the company is well-positioned to achieve their goals and contribute to the advancement of healthcare in the global community.